Therapeutic activity of ambroxol theophyllinacetate in chronic obstructive pulmonary diseases

In an open study, 50 patients suffering from chronic obstructive pulmonary disease in an acute infectious phase were treated with ambroxol theophyllinacetate. The drug was given orally in a dosage of 100 mg BID for ten days. Viscosimetric data showed a significant decrease of viscosity of the mucus, leading to easier expectoration and reduction in the severity and frequency of cough. These improvements had positive effects on respiratory function and on the condition of the patients.